Increase in number of mergers and acquisitions is
anticipated to help the industry boost in the coming years. For instance, in
March 2018, Laborie had entered into a $239 million deal to buy Cogentix
Medical. The takeover will give Laborie control of devices for treatment of
overactive bladder (OAB) and stress urinary incontinence (SUI). Cogentix built
its business around a urology portfolio spearheaded by a neuromodulation device
to treat overactive bladder and a soft-tissue bulking agent for managing stress
urinary incontinence.
Growth in number of product launches is expected to help the
industry flourish during the forecast period. For instance, the FDA approved
cefiderocol (FETROJA) in patients of 18 years of age or older who have limited
or no alternative treatment options, for complicated urinary tract infections
(cUTI), including pyelonephritis, caused by susceptible Gram-negative
microorganisms such as Escherichia coli, Klebsiella pneumoniae, Proteus
mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
Explore More Insights@ https://www.alliedmarketresearch.com/request-toc-and-sample/10908
Major factors affecting the industry include urinary
incontinence and aging in women. Moreover, increase in the number of product
launches and approvals for generics is expected to fuel the market growth. Various
major companies focus on leveraging strategic alliances such as expanding into
multiple sectors, which are more sensitive to driving the industry.
Key Segment Covered:
Pharmacotherapy:
- Fesoterodine
- Tolterodine
- Trospium
- Anticholinergics
- Solifenacin
- Oxybutynin
- Darifenacin
Diseases type:
- Idiopathic Bladder Overactivity
- Neurogenic Bladder Overactivity
Key Benefits:
- The
analytical depiction of the global overactive bladder treatment industry
along with the current trends and future estimations to determine the
imminent investment pockets.
- The
report presents information related to key drivers, restraints, and
opportunities along with detailed analysis of the global overactive
bladder treatment market share.
- The
current market is quantitatively analyzed from 2020 to 2027 to highlight
the global overactive bladder treatment market growth scenario.
- Porter’s
five forces analysis illustrates the potency of buyers & suppliers in
the market.
- The
report provides a detailed global overactive bladder treatment market
analysis based on competitive intensity and how the competition will take
shape in coming years.
Leading market Players:
- Astellas Pharma, Inc.,
- Pfizer, Inc.,
- Teva Pharmaceutical Industries Limited,
- Allergan, Plc,
- Medtronic plc,
- Mylan N.V.,
- Endo International plc,
- Hisamitsu Pharmaceutical Co., Inc.,
- Sanofi,
- Aurobindo Pharma Limited
0 Comments